Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v2-FR | Version v2-FR | |
|---|---|---|
| Language | French | French |
| Date Updated | 2026-01-06 | 2026-01-06 |
| Drug Identification Number | 02241472 | 02241472 |
| Brand name | TAMIFLU | TAMIFLU |
| Common or Proper name | Oseltamivir | Oseltamivir |
| Company Name | HOFFMANN-LA ROCHE LIMITED | HOFFMANN-LA ROCHE LIMITED |
| Ingredients | OSELTAMIVIR | OSELTAMIVIR |
| Strength(s) | 75MG | 75MG |
| Dosage form(s) | CAPSULE | CAPSULE |
| Route of administration | ORAL ORAL | ORAL ORAL |
| Packaging size | Blister pack of 10 | Blister pack of 10 |
| Additional packaging sizes | ||
| ATC code | J05AH | J05AH |
| ATC description | DIRECT ACTING ANTIVIRALS | DIRECT ACTING ANTIVIRALS |
| Reason for shortage | Demand increase for the drug. | Demand increase for the drug. |
| Anticipated start date | 2026-03-30 | 2026-03-30 |
| Actual start date | ||
| Estimated end date | 2026-05-01 | 2026-05-01 |
| Actual end date | ||
| Shortage status | Anticipated shortage | Anticipated shortage |
| Tier 3 Status | No | No |
| Company comments | Anticipated shortage due to usage of 75mg for compounding purposes with the recent market shortages of Tamiflu Powder for Oral Suspension. The order quantities will be monitored and allocated on an as needed basis to ensure equitable distribution. | Anticipated shortage due to usage of 75mg for compounding purposes with the recent market shortages of Tamiflu Powder for Oral Suspension. The order quantities will be monitored and allocated on an as needed basis to ensure equitable distribution. |
| Health Canada comments |